Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial

M Davies, TR Pieber, ML Hartoft-Nielsen, OKH Hansen… - Jama, 2017 - jamanetwork.com
Importance Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the
treatment of type 2 diabetes and are all currently available as an injection. Objectives To
compare the effects of oral semaglutide with placebo (primary) and open-label
subcutaneous semaglutide (secondary) on glycemic control in patients with type 2 diabetes.
Design, Setting, and Patients Phase 2, randomized, parallel-group, dosage-finding, 26-week
trial with 5-week follow-up at 100 sites (hospital clinics, general practices, and clinical …